Topics:
Heart Failure (HF)
Session number: 1613
Session title: Heart Failure with preserved ejection fraction
Authors: McKelvie, Robert (Hamilton, CA)
View the Webcast
Heart failure with preserved ejection fraction is common and is associated with a significant degree of mortality and morbidity. There have been many smaller studies demonstrating that a number of different therapies, including angiotensin converting enzyme inhibitors and beta-blockers, relieve the symptoms and signs of this form of heart failure. However, there have been few large randomized controlled trials examining therapies for these patients. The large randomized controlled trials that have been completed have not demonstrated clear benefit with any of the therapies tested.
Teaching objective of the lecture:
The objective of the lecture is to review the pharmacologic therapies that have been examined in large clinical trials designed to assess the effects on mortality and morbidity. As well, information about ongoing trial will be reviewed.
Take home messages:
- Many pharmacologic therapies have been demonstrated to relieve symptoms and signs related to heart failure with preserved ejection fraction
- The published large randomized controlled trials have not demonstrated a clear benefit with any of the pharmacologic therapies examined
- It is important to aggressively treat the factors responsible, such as hypertension, for the development of this form of heart failure
The content of this article reflects the personal opinion of the
author/s and is not necessarily the official position of the
European Society of Cardiology.